Evaxion A (EVAX) Net Income towards Common Stockholders (2020 - 2026)
Evaxion A (EVAX) reported Net Income towards Common Stockholders of -$3.6 million for Q1 2026, down 129.68% on a YoY basis from $12.2 million in Q1 2025, and up 38.68% quarter-over-quarter from -$5.9 million in Q4 2025.
Evaxion A (EVAX) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Evaxion A has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$3.6 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 129.68% year-over-year to -$3.6 million; the trailing twelve-month figure through Mar 2026 stood at -$9.8 million (up 26.85% YoY), and the FY2025 full-year result was -$7.7 million, up 27.07% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$3.6 million, up from -$5.9 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $4.6 million in Q3 2025, with the low at -$13.2 million in Q1 2023.
- Historically, Net Income towards Common Stockholders has averaged -$4.4 million across 5 years, with a median of -$4.8 million in 2025.
- The largest YoY upside for Net Income towards Common Stockholders was 338.66% in 2025 against a maximum downside of 232.33% in 2025.
- Evaxion A's Net Income towards Common Stockholders stood at -$6.9 million in 2022, then soared by 34.18% to -$4.5 million in 2023, then increased by 19.77% to -$3.6 million in 2024, then sank by 63.08% to -$5.9 million in 2025, then soared by 38.68% to -$3.6 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$3.6 million (Q1 2026), -$5.9 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 727.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.63 Mn |
| Dec 31, 2025 | -5.92 Mn |
| Sep 30, 2025 | 4.62 Mn |
| Jun 30, 2025 | -4.83 Mn |
| Mar 31, 2025 | -1.58 Mn |
| Dec 31, 2024 | -3.63 Mn |
| Sep 30, 2024 | -1.94 Mn |
| Jun 30, 2024 | -6.20 Mn |
| Mar 31, 2024 | 1.19 Mn |
| Dec 31, 2023 | -4.52 Mn |
| Sep 30, 2023 | -5.68 Mn |
| Jun 30, 2023 | -5.68 Mn |
| Mar 31, 2023 | -13.20 Mn |
| Dec 31, 2022 | -6.87 Mn |
| Sep 30, 2022 | -6.09 Mn |
| Jun 30, 2022 | -4.77 Mn |
| Mar 31, 2022 | -5.79 Mn |
| Dec 31, 2021 | -5.72 Mn |
| Sep 30, 2021 | -5.25 Mn |
| Jun 30, 2021 | -6.82 Mn |